Search Videos and More
Document
Contraception in Patients With a History of Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of contraception I patients with a history of breast cancer.
Document
CDK4/6 Inhibitors after Progression on CDK4/6 Inhibitor in Patients With Hormone Receptor-Positive/HER2-negative Advanced Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of CDK4/6 inhibitors after progression on CDK4/6 inhibitor in patients with hormone receptor-positive/HER2-negativ
News
Mind and Body: Prioritizing Mental Health
A lump felt in the shower. Weight loss. Night sweats. The anticipation — refreshing the portal for results, awaiting a phone call, wondering if your life will change in an instant.
News
Can Metastatic Breast Cancer Be Cured?
When Yvonne Fantaci discovered she had breast cancer at age 60, it had already spread to her lungs, liver, and elsewhere. Fantaci felt blindsided. She was otherwise completely healthy. She never expected such a shocking diagnosis.
Video
Ann Partridge, MD, MPH Presents PROs from the COMET Study
Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data.
Video
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study
Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Video
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor
Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Video
Jennifer Ligibel, MD Discusses Weigh Loss Intervention
Dana-Farber's Jennifer Ligibel, MD reviews a telephone-based weight loss intervention that led to significant improvements in metabolic and inflammatory biomarkers associated with cancer recurrence according to new data.
Document
Capivasertib Plus Fulvestrant for Advanced Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of capivasertib plus fulvestrant in patients with advanced estrogen receptor-positive breast cancer.
Symposium
2024 SABCS Highlights
Dana-Farber Cancer Institute Faculty highlights from the 2024 San Antonio Breast Cancer Symposium.
Document
Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-Low and HER2-Ultralow Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of trastuzumab deruxtecan (T-DXd) for patients with metastatic, HER2-low and HER2-ultralow breast cancer.
News
Researchers Uncover Key Actor in Spread of Breast Cancer to the Brain
When breast cancer metastasizes, it often heads for the brain, where it can be exceptionally difficult to root out. The key to preventing the spread of the cancer, or thwarting it if it does reach the brain, is to understand the mechanism that turns stationary tumor cells into nomadic intruders.